NEUREN PHARMACEUTICALS LIMITED

3.11%

$19.00

Market Cap $2.399B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

Latest Threads

Tag

Subject

NEU

Share Price

275 276 277

18:08

16K

8.3M

18:08

Last post kens

16K

8.3M

NEU

NEU chart

38 39 40

15:32

2.3K

1.3M

15:32

Last post What A Gas

2.3K

1.3M

NEU

From the Professor - Formatted for easy read

01/09/25

2.9K

01/09/25

Last post WESTHOT

2.9K

NEU

The Professor- He’s back….

01/09/25

2.1K

01/09/25

Last post Tony barber

2.1K

NEU

Neuren Media and Analyst Coverage

31 32 33

01/09/25

1.9K

1.1M

01/09/25

Last post good1234

1.9K

1.1M

NEU

Ann: Investor Presentation, 27 August 2025

30/08/25

1.6K

30/08/25

Last post monopolywharf

1.6K

NEU

The Field of Play for NEU through the eyes of Ken (AKA The Professor)

29/08/25

21K

29/08/25

Last post baldwidx

21K

NEU

Katelin’s Turn is HERE!!!

4 5 6

29/08/25

346

222K

29/08/25

Last post mellan

346

222K

See All Discussions

Timeline

Application for quotation of securities - NEU
28 Aug 16:43	Share

Investor Presentation, 27 August 2025
27 Aug 11:21	Share

H1 2025 profit after tax A$15m, up from A$8m in H1 2024
27 Aug 09:24	Share

Half Yearly Report and Accounts
27 Aug 09:21	Share

First site initiated for Neuren's PMS Phase 3 trial
25 Aug 09:27	Share

Application for quotation of securities - NEU
12 Aug 16:12	Share

Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline
08 Aug 09:16	Share

DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024
07 Aug 09:51	Share

Change of Director's Interest Notice - J Pilcher
22 Jul 09:30	Share

Application for quotation of securities - NEU
22 Jul 09:21	Share

Notification regarding unquoted securities - NEU
09 Jul 17:03	Share

Application for quotation of securities - NEU
30 Jun 17:49	Share

US patent allowed for NNZ-2591 to treat Pitt Hopkins
26 Jun 09:25	Share

Notification of cessation of securities - NEU
25 Jun 17:26	Share

Update - Notification of buy-back - NEU
16 Jun 09:28	Share

Update - Notification of buy-back - NEU
16 Jun 09:07	Share

Update - Notification of buy-back - NEU
13 Jun 08:26	Share

Update - Notification of buy-back - NEU
12 Jun 07:45	Share

Update - Notification of buy-back - NEU
11 Jun 08:07	Share

Update - Notification of buy-back - NEU
10 Jun 08:33	Share

Update - Notification of buy-back - NEU
06 Jun 09:13	Share

Update - Notification of buy-back - NEU
05 Jun 07:50	Share

Notification of cessation of securities - NEU
04 Jun 16:30	Share

Update - Notification of buy-back - NEU
04 Jun 08:30	Share

Update - Notification of buy-back - NEU
03 Jun 08:38	Share

Update - Notification of buy-back - NEU
02 Jun 08:51	Share

Update - Notification of buy-back - NEU
30 May 08:41	Share

Update - Notification of buy-back - NEU
29 May 08:00	Share

Update - Notification of buy-back - NEU
28 May 07:31	Share

Results of Meeting
27 May 12:17	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $19.00		Change -0.610(3.11%)		Mkt cap ! $2.399B

Open	High	Low	Value	Volume
$19.63	$19.80	$18.90	$14.00M	726.6K

Buyers (Bids)

No.	Vol.	Price($)
2	1082	$18.90

Sellers (Offers)

Price($)	Vol.	No.
$19.01	1000	1

View Market Depth

No.	Vol.	Price($)
2	1082	18.900
1	5000	18.890
2	11770	18.880
2	1197	18.870
1	1000	18.850

Price($)	Vol.	No.
19.010	1000	1
19.040	1008	2
19.190	106	1
19.370	3000	1
19.390	1000	1

Last trade - 16.10pm 03/09/2025 (20 minute delay)


Last $18.93		Change -0.610 ( 3.73 %)
Open	High	Low	Volume
$19.56	$19.78	$18.90	202021
Last updated 15.59pm 03/09/2025 ?

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED

Latest Threads

Listen: HotCopper Wire Podcast 023 – Glowing gold, shining silver, and... wheat collusion?

Timeline

Featured News

Latest Videos

Neuren Pharmaceuticals (ASX:NEU) partner drug approved as first treatment for Rett syndrome

13 Mar 2023 10:53 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) receives FDA approval for Prader-Willi syndrome phase II trial

23 Jan 2023 11:16 (AEDT)

Latest Articles

Neuren Pharma jumps on DAYBUE sales win; short sellers' report now history

Dual-listed across the NASDAQ and ASX, Neuren Pharma (ASX:NEU) has jumped +7% down under in the morning Thursday session as...

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Neuren Pharma (ASX:NEU) has seen its shares jump over +11% as the company wins a patent to treat Pitt Hopkins Syndrome...

FDA OK for Neuren's first ever Phase 3 trial in children with Phelan-McDermid syndrome

Neuren has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News